100+ Free Arab Board Urology Clinical Exam Practice Questions

Prepare for the Arab Board of Health Specializations Urology Final Clinical and Oral Exam exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Arab Board Specialty Certification Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Sample Arab Board Urology Clinical Exam Practice Questions

Try these sample questions to test your Arab Board Urology Clinical Exam exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 62-year-old male with a baseline PSA of 6.8 ng/mL undergoes multiparametric MRI (mpMRI) of the prostate, which demonstrates a 14 mm PI-RADS 5 lesion in the right peripheral zone with abutment of the capsule but no gross extraprostatic extension. Targeted and systematic transperineal biopsies reveal ISUP Grade Group 2 (Gleason score 3+4=7) adenocarcinoma in 3 targeted cores (maximum core involvement 40%), and all systematic cores from the left lobe are benign. What is the most appropriate next clinical management discussion with this patient?

A.Immediate initiation of androgen deprivation therapy monotherapy

B.Discussion of definitive local therapies (radical prostatectomy or external beam radiotherapy) versus carefully monitored active surveillance

C.Immediate bilateral pelvic lymph node dissection alone as a diagnostic procedure

D.Systemic chemotherapy with six cycles of docetaxel

Explanation: This patient has favorable intermediate-risk prostate cancer (ISUP Grade Group 2, PSA < 10 ng/mL, low volume Gleason 4 pattern, organ-confined). According to international EAU/AUA guidelines, definitive treatment options such as radical prostatectomy (open/robotic) or external beam radiation therapy (EBRT) +/- short-term ADT should be presented, while active surveillance may also be considered in highly selected patients with low-volume Gleason 3+4 disease. Systemic ADT monotherapy or upfront docetaxel chemotherapy is inappropriate for non-metastatic, localized intermediate-risk disease.

2A 66-year-old male who underwent robot-assisted laparoscopic radical prostatectomy 2 years ago for pT3aN0 prostate cancer with negative surgical margins had an undetectable postoperative PSA (<0.01 ng/mL). Routine surveillance reveals a confirmed PSA rise to 0.24 ng/mL, repeated 3 months later at 0.31 ng/mL. What is the established diagnosis and the standard-of-care next therapeutic step?

A.Biochemical recurrence; initiate salvage radiation therapy to the prostatic bed with consideration of short-term ADT

B.Benign anastomotic stricture; schedule urethral dilatation

C.Castration-resistant prostate cancer; start enzalutamide monotherapy

D.Widespread bone metastasis; initiate palliative zoledronic acid without imaging

Explanation: Biochemical recurrence (BCR) following radical prostatectomy is defined by consensus as a confirmed PSA value >= 0.20 ng/mL with a subsequent confirmatory rise. Salvage radiation therapy (SRT) to the prostatic bed (with or without short-term androgen deprivation therapy) offers the greatest curative potential when delivered early, ideally when the PSA is <= 0.5 ng/mL. Neither CRPC systemic agents nor bisphosphonates are indicated without documented castration resistance or proven metastatic bone lesions.

3A 71-year-old male presents with bone pain and is diagnosed with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Staging 68Ga-PSMA PET/CT demonstrates multiple avid lesions across the lumbar spine, pelvis, and ribs (high-volume disease by CHAARTED criteria), with a baseline PSA of 185 ng/mL and normal organ function. What represents the current evidence-based first-line systemic management?

A.Triplet systemic therapy with ADT, docetaxel chemotherapy, and an AR pathway inhibitor (darolutamide or abiraterone)

B.Continuous bicalutamide 50 mg monotherapy

C.Immediate bilateral open orchiectomy alone without any further systemic agents

D.External beam radiation therapy to the prostate without systemic therapy

Explanation: Pivotal phase III randomized clinical trials (ARASENS and PEACE-1) established triplet therapy (androgen deprivation therapy [ADT] + docetaxel + darolutamide or abiraterone acetate with prednisone) as a superior standard of care for patients with de novo, high-volume metastatic hormone-sensitive prostate cancer (mHSPC), providing substantial overall survival benefits. ADT combined with an AR pathway inhibitor (doublet therapy) is also an approved standard, whereas first-generation antiandrogen monotherapy (bicalutamide) or local radiotherapy alone without systemic blockade is completely inadequate.

4During evaluation of a 60-year-old male with mild lower urinary tract symptoms, multiparametric MRI of the prostate demonstrates a 12 mm well-circumscribed, encapsulated, round nodule within the transition zone with heterogeneous T2 signal and no diffusion restriction or focal early enhancement. According to PI-RADS v2.1 guidelines, how should this finding be categorized?

A.PI-RADS 2 (Clinically significant cancer is unlikely)

B.PI-RADS 4 (Clinically significant cancer is likely)

C.PI-RADS 5 (Clinically significant cancer is highly likely)

D.PI-RADS 1 (Normal background tissue without any distinct nodule)

Explanation: In PI-RADS v2.1, the transition zone is primarily evaluated using T2-weighted imaging. A well-circumscribed, completely encapsulated or circumscribed heterogeneous nodule in the transition zone is a classic benign prostatic hyperplasia (BPH) nodule, designated as PI-RADS 2 (clinically significant cancer is unlikely to be present). PI-RADS 4 and 5 in the transition zone require non-circumscribed, lenticular, or spiculated margins with marked diffusion restriction on DWI/ADC.

5A 64-year-old male with clinically localized prostate cancer (PSA 16 ng/mL, cT2b, ISUP Grade Group 4 [Gleason 4+4=8]) is scheduled for robot-assisted radical prostatectomy. A validated nomogram calculates an estimated pelvic lymph node involvement risk of 22%. What constitutes the standard anatomical template for extended pelvic lymph node dissection (ePLND) in this patient?

A.Removal of external iliac, obturator fossa, and internal iliac (hypogastric) nodal packets up to the common iliac bifurcation bilaterally

B.Removal of superficial inguinal and femoral canal lymph nodes only

C.Sampling of the fat pad overlying the anterior bladder neck exclusively

D.Excision of retroperitoneal paracaval and para-aortic lymph nodes only

Explanation: When performing an extended pelvic lymph node dissection (ePLND) during radical prostatectomy for intermediate- or high-risk prostate cancer (nomogram risk > 5-7%), the standard template includes the external iliac nodes, obturator fossa nodes, and internal iliac (hypogastric) nodes bilaterally, bounded proximally by the bifurcation of the common iliac vessels and distally by the node of Cloquet/Cooper's ligament. Limited obturator sampling misses more than 50% of positive nodal metastases.

6A 57-year-old healthy male undergoes prostate biopsy for a PSA of 4.4 ng/mL. Histopathology reveals ISUP Grade Group 1 (Gleason 3+3=6) adenocarcinoma in 1 out of 14 cores involving 10% of that core. Digital rectal examination is normal (cT1c), and multiparametric MRI shows no PI-RADS >= 3 lesions. What is the internationally recommended preferred primary management strategy?

A.Active surveillance with serial PSA, digital rectal examination, periodic mpMRI, and confirmatory/surveillance biopsies

B.Immediate total androgen deprivation with GnRH agonist monotherapy for 3 years

C.Urgent radical cystoprostatectomy with urinary diversion

D.High-dose external beam radiation therapy combined with long-term ADT

Explanation: Active surveillance (AS) is the internationally endorsed preferred management strategy for men with very low-risk and low-risk localized prostate cancer (ISUP Grade Group 1, cT1c-cT2a, PSA < 10 ng/mL, low core volume). AS preserves quality of life by avoiding immediate erectile and urinary toxicities while maintaining the opportunity for curative intervention upon evidence of true disease reclassification or progression. Radical extirpation or high-dose RT with ADT represents overtreatment with unnecessary morbidity.

7A 75-year-old male with metastatic castration-resistant prostate cancer (mCRPC) has disease progression following prior treatment with docetaxel chemotherapy and enzalutamide. A 68Ga-PSMA-11 PET/CT scan demonstrates intense, diffuse PSMA expression across numerous bone metastases without any PSMA-negative discordant FDG lesions. Based on the phase III VISION trial, which targeted radiopharmaceutical therapy is indicated?

A.177Lutetium-PSMA-617 (177Lu-PSMA-617) radioligand therapy

B.Intravenous Bacille Calmette-Guérin (BCG) immunotherapy

C.Radium-223 dichloride combined simultaneously with abiraterone acetate

D.Intra-arterial cisplatin hepatic infusion

Explanation: The phase III VISION trial demonstrated that 177Lu-PSMA-617, a beta-emitting radioligand that selectively binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells, significantly improved overall survival and progression-free survival in patients with PSMA-positive mCRPC previously treated with an AR pathway inhibitor and taxane chemotherapy. Radium-223 combined with abiraterone is contraindicated due to increased fracture and death rates (ERA 223 trial).

8When comparing transperineal (TP) prostate biopsy to transrectal ultrasound-guided (TRUS) prostate biopsy in clinical practice, which established advantage of the transperineal approach is most supported by urological literature?

A.Virtually eliminating the risk of post-biopsy urosepsis and severe infectious complications

B.Completely eliminating the need for any local or regional anesthesia

C.Reducing the operative time to less than two minutes

D.Eliminating the risk of post-procedure hematuria and urinary retention

Explanation: The primary clinical driver for adopting transperineal (TP) prostate biopsy is the dramatic reduction (approaching zero percent) in post-biopsy infectious complications and urosepsis because the biopsy needle traverses disinfected perineal skin rather than the bacteria-laden rectal mucosa. TP biopsy does not eliminate hematuria or urinary retention, and it still requires adequate local, periprostatic, or general anesthesia.

9A 67-year-old male with high-risk localized prostate cancer (PSA 26 ng/mL, Gleason 4+4=8, cT2c) elects to undergo definitive external beam radiation therapy (EBRT). According to major international guidelines, what is the standard recommended duration of accompanying androgen deprivation therapy (ADT)?

A.Long-term ADT for 24 to 36 months (neoadjuvant, concurrent, and adjuvant)

B.Short-term ADT for exactly 2 weeks only

C.No ADT is recommended when radiation doses exceed 70 Gy

D.Lifelong continuous ADT until death

Explanation: Multiple prospective randomized clinical trials (e.g., EORTC 22961, RTOG 9202) have established that for high-risk localized or locally advanced prostate cancer treated with definitive radiotherapy, long-term androgen deprivation therapy (24 to 36 months total) confers a significant overall survival and metastasis-free survival advantage over short-term (4-6 months) ADT or radiation alone. Lifelong ADT is unnecessary and causes excessive long-term metabolic toxicity in non-metastatic disease.

10A 63-year-old male presents with early biochemical recurrence (PSA 0.55 ng/mL) 18 months following radical prostatectomy. Conventional abdominopelvic CT and technetium-99m bone scintigraphy are reported as negative. Which molecular imaging modality offers the highest diagnostic sensitivity and positive predictive value for localizing the recurrent disease site at this PSA level?

A.68Ga-PSMA-11 or 18F-DCFPyL PSMA-PET/CT

B.18F-FDG PET/CT

C.Non-contrast abdominal ultrasound

D.Plain pelvic radiography (pelvic X-ray)

Explanation: PSMA-targeted PET/CT (utilizing 68Ga-PSMA-11 or 18F-DCFPyL) is significantly more sensitive than conventional imaging (CT and bone scan) and 18F-FDG PET for detecting prostate cancer recurrence at low serum PSA levels (detecting lesions in >50% of patients with PSA between 0.5 and 1.0 ng/mL). 18F-FDG is generally insensitive in prostate cancer due to low basal glucose metabolism in indolent or moderately differentiated adenocarcinomas.

About the Arab Board Urology Clinical Exam Exam

The Arab Board Urology Final Clinical and Oral Exam is the culminating exit qualification administered by the ABHS Scientific Council of Urology. It rigorously evaluates senior urology residents on diagnostic imaging (CT urogram, multiparametric MRI prostate, nuclear scintigraphy), urodynamics interpretation, operative surgical decision-making, oncology management, endourology, pediatric urology, female pelvic medicine, and urological emergencies through structured clinical stations and oral viva.

Assessment

Structured clinical case scenarios, radiological and urodynamic station evaluations, and interactive oral viva panels testing diagnostic judgment and operative urologic decision-making.

Time Limit

Approximately 2 to 3 hours

Passing Score

Approximately 60% cumulative pass standard across clinical and oral stations as established by the ABHS Scientific Council of Urology.

Exam Fee

Set by ABHS and national councils (Arab Board of Health Specializations (ABHS))

Arab Board Urology Clinical Exam Exam Content Outline

12%

Urologic Oncology — Prostate Cancer

PSA kinetics, mpMRI/PI-RADS interpretation, targeted/systematic biopsy, active surveillance, nerve-sparing radical prostatectomy, radiation therapy, pelvic lymph node dissection templates, biochemical recurrence, and advanced/metastatic hormone-sensitive and castration-resistant systemic therapies.

12%

Urologic Oncology — Bladder & Upper Tract Urothelial Carcinoma

High-quality TURBT, NMIBC risk stratification, intravesical BCG induction and maintenance, BCG-unresponsive definitions and salvage options, radical cystectomy with extended PLND, orthotopic neobladder versus ileal conduit, and upper tract urothelial carcinoma (UTUC) nephroureterectomy and kidney-sparing strategies.

10%

Urologic Oncology — Kidney & Adrenal Masses

Solid and cystic renal mass management (Bosniak classification), partial versus radical nephrectomy, warm and cold ischemia management, renal vein/IVC thrombus staging (Levels I–IV), hereditary renal cancer syndromes (VHL, BHD), systemic targeted/immunotherapies, and adrenal mass workup including pheochromocytoma optimization.

Urologic Oncology — Testicular & Penile Malignancies

Testicular germ cell tumor staging, serum tumor marker kinetics (AFP, beta-hCG, LDH), primary retroperitoneal lymph node dissection (RPLND) templates, post-chemotherapy residual mass management, seminoma vs non-seminoma protocols, penile squamous cell carcinoma staging, and dynamic sentinel node biopsy/inguinofemoral lymphadenectomy.

14%

Endourology & Nephrolithiasis

Surgical management of acute obstructing infected urolithiasis, PCNL access techniques (prone vs supine, fluoroscopic vs ultrasound-guided), semirigid and flexible ureterorenoscopy (URS/RIRS), laser lithotripsy parameter optimization (dusting vs pop-dusting vs fragmentation), shock wave lithotripsy (ESWL), metabolic 24-hour urine evaluation, and encrusted stent retrieval.

12%

Pediatric Urology

Antenatal hydronephrosis evaluation, vesicoureteral reflux (VUR) grading and management (endoscopic Deflux vs Cohen/Politano-Leadbetter reimplantation), posterior urethral valves (PUV) primary ablation and long-term renal preservation, ureteropelvic junction obstruction (UPJO) Anderson-Hynes pyeloplasty, hypospadias repairs (TIP/Snodgrass, two-stage), cryptorchidism orchidopexy timing, testicular torsion, and spina bifida neurogenic bladder.

10%

Female Urology, Urodynamics & Pelvic Reconstruction

Comprehensive urodynamic study (UDS) curve interpretation (filling cystometry, pressure-flow, BOOI, detrusor-sphincter dyssynergia), stress urinary incontinence surgery (midurethral slings, autologous pubovaginal fascial slings, AUS), vesicovaginal fistula (VVF) surgical repair and flap interposition, urethral diverticulectomy, and overactive bladder refractory pathways (Botox, SNM, PTNS).

Andrology, Male Infertility & Sexual Medicine

Azoospermia diagnostic algorithm (obstructive vs non-obstructive), micro-TESE techniques, varicocele repair indications, erectile dysfunction stepwise treatment (PDE5i, intracavernosal injections, inflatable penile prosthesis IPP implantation), Peyronie's disease plaque assessment and surgical straightening, and acute priapism management (ischemic vs non-ischemic).

Benign Prostatic Hyperplasia (BPH) & LUTS

Guideline-directed medical therapy (alpha-1 blockers, 5-ARIs, PDE5 inhibitors), monopolar vs bipolar TURP, holmium laser enucleation of the prostate (HoLEP), minimally invasive surgical therapies (MIST like Rezūm, UroLift, Aquablation), simple open/robotic prostatectomy for large glands, and intraoperative TURP syndrome management.

Urologic Emergencies, Trauma & Genitourinary Reconstruction

Renal trauma grading (AAST I–V) and indications for angioembolization vs open exploration, ureteral injury recognition and repair (Boari flap, psoas hitch, transureteroureterostomy), intraperitoneal vs extraperitoneal bladder rupture, anterior vs posterior urethral trauma, Fournier's gangrene rapid surgical debridement, and testicular rupture.

How to Pass the Arab Board Urology Clinical Exam Exam

What You Need to Know

Passing score: Approximately 60% cumulative pass standard across clinical and oral stations as established by the ABHS Scientific Council of Urology.
Assessment: Structured clinical case scenarios, radiological and urodynamic station evaluations, and interactive oral viva panels testing diagnostic judgment and operative urologic decision-making.
Time limit: Approximately 2 to 3 hours
Exam fee: Set by ABHS and national councils

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Arab Board Urology Clinical Exam Study Tips from Top Performers

1Practice structured oral viva delivery with peers using the standard format: clinical history, targeted physical exam, diagnostic review (CT urogram, MRI PI-RADS, MAG3 renogram), and step-by-step operative strategy including complication management.

2Thoroughly review EAU and AUA clinical practice guidelines, especially on prostate cancer risk stratification, BCG-unresponsive NMIBC management, stone surgical algorithms, and renal mass treatment pathways.

3Master urodynamic trace interpretation (filling cystometry, detrusor overactivity, leak point pressures, BOOI calculation, and detrusor sphincter dyssynergia) and radiological criteria such as Bosniak cystic renal mass classification and PI-RADS v2.1.

Frequently Asked Questions

What is the examination format for the Arab Board Urology Final Clinical and Oral Exam?

The ABHS Final Urology Clinical Exam comprises structured objective clinical stations (OSCE), diagnostic imaging and urodynamic curve interpretation tables, and face-to-face oral viva panels conducted by senior consultant examiners evaluating operative decision-making, crisis management, and evidence-based urology guidelines.

What passing score standard is applied by the Arab Board Scientific Council of Urology?

A candidate must achieve an overall aggregate score of approximately 60% across all stations and oral viva components, with mandatory minimum competency thresholds demonstrated in clinical safety, oncology guidelines, and emergency management.

How should I structure my answers during the oral viva examination?

Utilize a systematic surgical approach: begin with patient stabilization/resuscitation when applicable, state your primary diagnosis and differential, detail focused diagnostic investigations (imaging, labs, urodynamics), outline clear treatment pathways (medical, endourological, or open/robotic operative), and discuss intraoperative contingency plans and postoperative surveillance.

How does this 100-question practice bank align with the oral and clinical examination?

This resource provides an English-language clinical MCQ simulation adapting high-yield oral viva scenarios, diagnostic imaging questions, urodynamic traces, and complex surgical decision-making algorithms directly aligned with the ABHS Urology curriculum.

100+ Free Arab Board Urology Clinical Exam Practice Questions

Explore More Arab Board Specialty Certification Exams

Arab Board Pediatrics Part 1 Written Exam (ABHS)

Arab Board Anatomic Pathology Part 1 Written Exam (ABHS)

Arab Board Anesthesia and Intensive Care Final Clinical and Oral Exam (ABHS)

Arab Board Anesthesia and Intensive Care Final Written Exam (ABHS)

Arab Board Anesthesia Part 1 Written Exam (ABHS)

Arab Board Clinical Pathology Part 1 Written Exam (ABHS)